1 May 2017
Following the 12th November 2018 announcement of the exercising of all the remaining warrants initially allocated to Wogen there are now no share warrants remaining.
|YD+ Others Placing : Others||
|Atlas Tranche 1||0
|Atlas Tranche 2||0
[1 – it is not clear from the RNS’s which of the two issuing blocks have so far been consumed. The Yellow Dragon ‘YD’ component of the first block, some 25Million warrants, was exercised on the 13th April 2017. RNS 26-9-18 confirms that the remaining block of 289,019 warrants expired without being exercised, as mentioned by Chika in an email to one of the LSE BB members.]
[2 – The Wogen warrants were first shown as being granted in practise in the RNS on the 8th June 2017, so possibly these had been conditional to Wogen before the final repayment of the Barak loan was made.]
[3 – The Afritin demerger evidently resulted in the 3,507,975 warrants previously being listed as ‘Others’ being revoked, to be replaced with 371,708 listed here as ‘Afritin Demerger’. The 17th November 2017 RNS which refers to the adjustment does not explicitly list the warrant price, or expiration date of the adjusting warrants. The 371,708 were subsequently reallocated to Darwin, Wogen (note 4) and Atlas (note 5), so the entry 'Afritin Demerger' was removed.]
[4 - Increased from 15,000,000 to 15,197,368 with change of strike price from 7.0p to 6.9p around the 8th Nov 2017 to reflect Afritin demerger.]
[5 - Increased from 6,250,000 to 6,332,236 with change of strike price from 14.4p to 14.2p after Afritin and then to 13.84p in March 2018 following 22.2M USD equity raise.]
[6 - Increased from 4,861,111 to 4,925,073 with change of strike price from 14.4p to 14.2p after Afritin and then to 13.84p in March 2018 following 22.2M USD equity raise.]
The total amount raised from the sale of warrants since the start of 2017 is GBP 5,199,434.
How the warrants played out.
This article only conveys the personal opinion of the author. Whilst every effort is made to ensure the content is accurate, we cannot guarantee the accuracy of the data shown. This article does not constitute professional, financial or investment advice and must not be used as a basis for making investment decisions.
Site content is not authorised by the FCA and you are not safeguarded by the Investor Protection measures of the Financial Services and Markets Act 2000. See our full disclaimer